Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2023 Earnings Call Transcript

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2023 Earnings Call Transcript November 9, 2023

Accelerate Diagnostics, Inc. beats earnings expectations. Reported EPS is $0.14, expectations were $-0.94.

Operator: Good day, and welcome to the Accelerate Diagnostics, Inc. 2023 Third Quarter Results Conference Call. All participant’s will be in listen-only mode. After today’s presentation, there will be a question-and-answer session. Please note this event is being recorded. I would now like to turn the conference over to Laura Pierson of Accelerate Diagnostics. Please go ahead.

Laura Pierson: Before we begin, it is important to share that information presented during this call may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include projections, statements about our future and those that are not historical facts. All forward-looking statements that are made during this conference call are subject to risks, uncertainties and other factors that could cause our actual results to differ materially. These are discussed in greater detail in our annual report on Form 10-K for the year ended December 31, 2022, and other reports we file with the SEC. It is my pleasure to now introduce the company’s President and CEO, Jack Phillips.

Jack Phillips: Thank you, Laura. Good afternoon, everyone, and welcome to our third quarter earnings call. In the quarter, we initiated our clinical trial for ARC, continue to hit development milestones with our Wave platform and continue to grow the market through our partnership with Becton Dickinson. Turning first to ARC. As a reminder, the ARC system is designed for clinical laboratories as a simple load and go workflow that automates direct from positive blood culture sample preparation for downstream microbial identification using MALDI-TOF. This solution enables on-demand processing of samples without the need for an overnight culture incubation, reducing the wait time for identification results. Customers will now have an automated, cost-competitive alternative for rapid positive blood culture ID compared to molecular solutions by using their existing MALDI-TOF systems.

Clinical laboratories are under pressure to run FDA-cleared devices with increased legislation and enforcement of laboratory developed tests. Thus, there will be great value in providing labs with an FDA-cleared device. We have already initiated our clinical trial and one site has already completed fresh sample enrollment. Our intent is to submit to the FDA over the coming months, which will ensure seamless laboratory adoption with the first FDA-cleared automated sample preparation. We are making great progress with ARC and hopefully, more exciting news to come shortly. Moving on to Wave, our next-generation rapid AST platform. We made good progress in the quarter and achieved several milestones. As a reminder, Wave will provide a comprehensive susceptibility testing menu, which will address both the 130 million tests performed from isolated colonies, as well as the over seven million tests performed from positive blood culture samples globally.

Based on customer workflow pain points, we built Wave to optimize lab workflows. Key differentiators between Wave and existing emerging susceptibility platforms includes high throughput sample, processing with improved time to result of less than 4.5 hours on average, random access for continuous sample loading and platform scalability to service all hospital segments. Wave Beta modules are now fully operational in our labs, the systems performed well with minimal challenges have great reliability and our lab technicians love the easy-to-use features. Time to result and performance continues to look good. We have developed a comprehensive image library for Evergreen Data analysis. Our goal is to seek clearance for approximately 300 gram negative bug drug combinations.

This is over twice the size of the current menu on Pheno. Most results are available well within 4.5 hours. We are seeing Drug-Induced Morphology changes well within 4.5 hours, which is what allows us to produce accurate early results. Time to result is a significant differentiator of the Wave system, by enabling labs to deliver same shift reporting for all Antibiotic Susceptibility Testing. Marketing has received significant voice of customer feedback on the WAVE system. Customers continue to confirm their excitement about WAVE, driven by the differentiated features of a consolidated AST menu on a single platform, same shift reporting scalability and improved economics. We plan to produce data readouts and submit an ESCMID abstract by year-end complete a preclinical trial early next year, followed by clinical trial for the Wave System and comprehensive Gram-Negative PVC menu.

We will look to submit to the FDA in mid-2024, with a commercial launch in early 2025. Overall, we are excited about the progress of the WAVE program and the promise of this Game-Changing Technology. With plans to begin pre-marketing activities next year, we are actively exploring wave commercialization options. Turning to our performance in the quarter, while the new contracted Pheno systems were less than anticipated for the quarter, our commercial partner, BD, continues to develop new opportunities and progress the funnel. We successfully secured a large portion of our customer base to long-term contracts in preparation for the WAVE launch. Now I would like to turn it over to David Patience, our Chief Financial Officer, to review our preliminary third quarter results.

David?

David Patience: Thank you, Jack, and good afternoon, everyone. In the third quarter, the US contracted 6 new Pheno instruments. We ended the quarter with a revenue-generating installed base of 339 Pheno instruments and a backlog of 70 instruments pending implementation. Additionally, we secured more than 20 existing customers, for multiyear contract extensions for rapid positive blood cultures susceptibility testing during the quarter. Net sales were approximately $3.3 million in the quarter and $9 million year-to-date. This compares to approximately $3 million and $9.8 million for the same period in the prior year. Our increase in quarterly revenues year-over-year, a decrease in revenue year-to-date has been driven by inconsistency of opportunities to secure capital revenues over the reported period.

Gross margin in the quarter was approximately 40% and 34% year-to-date, excluding $1.2 million in non-cash adjustments to inventory which compares to approximately 20% and 25% for the same period in the prior year. This increase was a result of lower service-related expenses, lower consumable manufacturing expenses and inclusive of sales of depreciated instruments. Selling, general and administrative expenses were $7.8 million for the quarter and $25.4 million year-to-date. This compares to $8.3 million and $30.4 million for the same period in the prior year. SG&A expenses, excluding noncash stock-based compensation, were $6.3 million for the quarter and $22.8 million year-to-date. This compares to $7.3 million and $23.9 million for the prior period.

Reductions in SG&A expenses are a result of lower employee-related expenses. Research and development expenses were $7.0 million for the quarter and $19.8 million year-to-date. This compared to $7.3 million and $20.9 million for the same period in the prior year. R&D expenses, excluding noncash stock-based compensation, were $6.7 million and $18.7 million year-to-date. This compares to $7.1 million and $19.8 million for the prior period. Reductions in R&D expense is driven by lower third-party consulting spend as our next-generation program Wave continues to advance through development. Our non-operating income for the quarter was $15.7 million, which included a fair value adjustment to our derivative liability Related to our convertible notes.

Our GAAP net income was approximately $910,000 for the quarter, while we had a net loss of approximately $48.6 million year-to-date resulting in net income per share of $0.06 for the quarter and a net loss of $4.13 per share year-to-date. Our net loss from operations, excluding non-cash stock-based compensation expense was $12.8 million for the quarter and $39.3 million year-to-date. Net cash used was $9.6 million for the quarter, and we ended the quarter with cash and investments of $21.2 million. Now, back to you, Jack.

Jack Phillips: Thanks, David. We would now like to open the lines for Q&A from our analyst.

See also 15 Biggest Diet Companies in the World and 12 Best Dividend Paying Stocks To Buy Now.

Q&A Session

Operator: We will now begin the question-and-answer session. And the first question comes from Andrew Brackmann with William Blair. Please go ahead.

Andrew Brackmann: Hey, guys. On for Andrew to actually taking our questions. Wondering on Wave, if you could talk about compared to the current standard of care?

Jack Phillips: Yeah. This is Jack, and no problem. I’m happy to take that one. Yes. So, today, just to put it in perspective, for example, Fino is really the market leader in time to resolve for rapid positive blood culture in the US at around 8 hours time to result. And so we’re close to being within that window of same ship reporting.

David Patience: When you look at some of the other solutions on the market and the age old traditional solutions that are on the market it’s often days before results can be realized and reported out. It’s really the same with — as we move into the isolate market, again, the much higher volume market, about 130 million tests globally. All of the automated solutions on the market are much greater than same shift. And it’s definitely next day. And so what customers are looking for and one of the key value propositions of wave is faster turnaround time to where you can actually get results for both positive blood culture and isolated colony testing in the same shift. And in 4.5 hours, as I mentioned, that’s what we’re seeing today.

And the impact of that is dramatic for patients because it allows clinicians to get those patients on the optimal therapy much quicker, day sooner than what the standard of care is today. And so as we talk about Wave in the market, we’re now out talking to many customers about Wave and the value proposition, while there’s several things that customers point to from automation, random access, drug bug menu, et cetera. One of the things that’s always on the top of the list relative to clinical value is time to result in the same ship period.

Andrew Brackmann: Understood. Appreciate the color there. Then just on maybe the BD partnership. Wondering if you guys can talk a little bit about the stage progression and funnel velocity with customers? And then maybe that’s varying by geography.

Jack Phillips: Yes, sure. Happy to take that one as well. And so first of all, I want to acknowledge that the quarter from a new contracted placement standpoint was disappointing for us. We had planned on having more new contracted instruments that we brought in. Several of these deals that we had planned on bringing in for the quarter were delayed. They’re still very active in the funnel, and we’re still working through those, but they were, in fact, delayed. From a funnel progression standpoint and also just building new opportunities, we continue to be very happy with our BD partnership. Absolutely, it’s taken some time to get the many sales reps up to speed, comfortable in selling rapid susceptibility testing, comfortable, comfortable with Pheno and — but they’re coming along.

The funnels are building, and we continue to make good progress — progressing the sales funnel. You mentioned in each geography. So that’s in the US very much the same in EMEA. The only thing I would add about EMEA is one of our challenges was a bit different in EMEA early days for a while, and it was really around the business model that we had that limited BD’s ability to really contract Phenos in a tender type environment, which is what EMEA is. And what I’m happy to say in the quarter, I don’t believe I mentioned this in the prepared remarks. But in the quarter, over the past month or so, we were successful at signing a new agreement with BD that really opens the door for them to now successfully respond to tenders in the EMEA markets and have Pheno and Arc they’re on the tenders within their overall BSI tenders that they’re responding to.

Andrew Brackmann: Understood. And then if you look at integration between yourself and BD, are there upcoming major milestones that we should be on the lookout for. Most of the team has been cross-trained already in, it’s more about execution here going forward.